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IntroductIon
Multiple sclerosis (MS) is an autoimmune demyeli-
nating disease of the central nervous system affect-
ing young adults. The therapeutic strategies include 
treatment of acute relapse, symptomatic- and the 
disease-modifying- treatment. Interferon beta (IFNβ) 
is a first line disease-modifying treatment available 
for the management of relapsing-remitting multiple 
sclerosis (RRMS) since 19931. The beneficial effect 
of IFNβ in MS is exerted by the reduction of disease 
activity as measured by decreased relapse rate, de-
layed progression of disability and reduced MRI ac-
tivity in relapsing-remitting MS1,2,3. Two types of re-
combinant IFNβ are commercially available: IFNβ-1b 
(subcutaneous IFNβ-1b, Betaferon®: Schering, Ber-
lin, Germany and subcutaneous IFNβ-1b, Extavia®: 
Novartis, Basel, Switzerland) and IFNβ-1a (intramus-
cular IFNβ-1a, Avonex®: Biogen, Cambridge, USA 
and subcutaneous IFNβ-1a, Rebif: Serono®, Genevè, 
Switzerland). The formulations of interferon-beta-1a 
and interferon-beta-1b show immunogenic properties 
and treated patients may develop binding (Babs) and 
neutralizing (Nabs) antibodies to these products. Nabs 
are a subset of Babs that prevent IFNβ from binding 
successfully to its receptor and in consequence block-
ing all the biologic effects of IFNβ4,5. In patients ex-
hibiting Nabs an attenuation of treatment effect6 and a 
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decrease in the IFN inducible proteins (i.e. myxovirus 
protein A-MxA, neopterin, β2-mocroglobulin) have 
been reported7,8. Considering the disease activity, their 
presence is associated with deterioration of clinical 
and radiological parameters. The incidence and titers 
of Nabs vary by the preparation of IFNβ used, dose, 
frequency and route of administration, treatment dura-
tion and type of assay being used1,2,4,9-12. 
Two types of antibodies, ie, Babs and Nabs, in-
dicate the antigenicity of IFNβ. Differences between 
detection assays, IFNβ subtype used in the assays, 
the timing of sampling, and differing product-specific 
cut-off levels for defining titers as negative, low, or 
high are all important considerations when measuring 
and interpreting Nab measurements. 
In the present study we aimed to assess the sensi-
tivity of two binding- and two neutralizing- available 
assays in patients with relapsing-remitting multiple 
sclerosis under treatment with interferon-beta.
MethodS
2.1.  Study design and patients
A total of 124 patients were included in the study. We 
focused on a sub-group of 64 patients who exhibited 
neutralizing activity as indicated by the cytopathic 
effect assay without the presence of Babs based on 
the capture ELISA assay. The blood samples of these 
patients were further assessed with Western blot as-
say for the detection of binding antibodies, in order 
to compare the sensitivity of the two assays. In addi-
tion, we examined 30 blood samples positive for Babs 
as detected using cELISA, by Western blot assay for 
further confirmation of our results. 
In the second part of the study, we performed real 
time PCR assay for MxA using 18s as a reference 
gene in 15 blood samples being positive and another 
15 samples negative for Nabs detection as indicated 
by the CPE assay in order to validate the accuracy of 
both methods. 
The patients included in this study (n = 124) experi-
enced intermediate disease activity and poor response 
to their IFNβ treatment, based on the assessment of 
Figure 1. Western blot assay. The first strip is used as a 
molecular weight marker. The adjacent strips belong to pa-
tients demonstrating (strips 3, 4, 5 and 6) samples with a 
band at the molecular weight level of the mouse positive 
control band were it is considered positive. Strips 1 and 2 
are negative.  
Figure 2. Diagrammatic presentation of Western blot assay 
results in blood samples which were characterized negative 
using the cELISA method. The first bar represents the posi-
tive and the second - one the negative samples.
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their treating neurologist. The intermediate disease 
activity was defined as one relapse during therapy; no 
or limited MRI activity (contrast-enhancing lesions 
and/or new T2 lesions), while doing poorly was de-
fined as multiple relapses or one relapse and extensive 
MRI activity (multiple contrast-enhancing lesions and 
new T2 lesions)13. 
Patients were diagnosed with relapsing-remitting 
multiple sclerosis based on the McDonald criteria and 
the revised McDonald criteria14,15 and received dis-
ease-modifying treatment with any of the three formu-
lations of interferon-β (INFβ-1b,Betaferon; INFβ-1a 
SC; INFβ-1a IM) for at least one year. Patients treated 
with subcutaneous IFNβ-1b (Extavia®) were not in-
cluded in this study because this formulation was not 
available.
Patients underwent serologic examination (Babs), 
using capture ELISA (cELISA) and Western blot as-
say. Nabs presence was determined via the assessment 
of the biological responsiveness to IFNβ using in vitro 
neutralizing activity - cytopathic effect assay and the 
MxA gene expression analysis using quantitative real-
time PCR.
Blood samples were drawn 12 hours after the last 
injection of correspondent IFNβ formulation. They 
were centrifuged and sera were stored in -200 C until 
their assessment.
2.2.  Measurement of Nabs and Babs
       2.2.1.  Binding assays
                   2.2.1.1. Capture ELISA (cELISA)
Binding antibodies were detected using the cELISA 
method as previously described16,17. In brief, 96-well 
microtitre plates (Nunc, Denmark) were coated over-
night with monoclonal anti-human IFNβ IgG BO2 
(Yamasa Shoyu Co, LtD, Tokyo, Japan) ‘capture’ 
antibody, at a concentration of 0.1 μg/well in 0.1 M 
carbonate-bicarbonate buffer. After plate was washed 
with phosphate-buffered saline (PBS) 0.05% Tween-
20 (PBS-T) and blocked with 0.5% non-fat dry milk 
solution for 1h. Then, wells were incubated for 1h 
either with PBS-T for the test wells, or with the ap-
propriate type of IFNβ for each patient diluted in in 
PBS-T (competitor wells) at a concentration of 150 
ng/mL or 1.5 μg/mL for IFNβ-1a and IFNβ-1b respec-
tively. Sera samples and negative control were diluted 
1:100 in PBS-T and incubated in duplicates in com-
petitor wells and test wells for 2h. The plate was then 
washed three times and IFNβ binding antibodies were 
detected by 1.5h incubation with a rabbit anti-human 
IgG secondary antibody conjugated with horseradish 
peroxidase (DakoCytomation, Glostrup, Denmark), 
diluted 1:6400 in PBS-T. After washing the plate 
3 times, TMB substrate (SIGMA, USA) was added 
resulting in color development. The reaction was 
stopped with 2N Sulfuric acid. Results were obtained 
in optical density (OD) units by spectrophotometric 
analysis at 405nm and were converted to binding units 
following comparison with a standard curve of serial 
dilutions of a positive reference sample known posi-
tive specimen. 
2.2.1.2.  Western blot assay (WB)
IFNβ was separated by sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE; 14% 
polyacrylamide). The proteins were then transferred 
to nitrocellulose membranes by electrotransfer. Then, 
free binding sites on the membranes were blocked in 
2% non-fat dry milk in PBS for 1 hour. The membranes 
were then washed twice with PBS-0.1% Tween-20 
(PBS-T) and cut into 2-mm strips.
A total of 1 mL test sample diluted 1:1000 in 
blocking buffer was incubated on a membrane strip 
overnight at room temperature. A mouse monoclo-
nal anti-human IFNβ antibody (Axell, Japan) and 
an internal positive control sample served as posi-
tive control subjects. For the negative control, serum 
from an IFNβ-naïve MS patient was used. Next, the 
strips were washed three times for 10 minutes with 
PBS-T and then incubated for 1 hour at room tem-
perature with phosphate-conjugated anti-mouse IgG 
antibodies (Axell, Japan) or phosphate-conjugated 
anti-human IgG antibodies (Axell, Japan) as appro-
priate. The strips were then washed twice with PBS-T 
and once with substrate buffer (100mM Tris HCl; pH 
9.5; 100mM MgCl2, 100mM NaCl). Finally, the strips 
were incubated with p-nitro blue tetrazolium chloride 
and 5-bromo-4-chloro-3-indolyl phosphate (Boeh-
ringer-Mannheim, Mannheim, Germany). After de-
velopment of the blue precipitate, strips were washed 
twice with double distilled water and then air dried. 
Samples with a band at the molecular weight level of 
the mouse positive control band were considered posi-
tive and the titer was determined by ELISA. 
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2.2.2.  Neutralizing assays
           2.2.2.1.  Cytopathic Effect assay (CPE) 
Neutralizing antibodies were detected using the an-
tiviral cytopathic effect (CPE) assay since it is recom-
mended by the World Health Organization (WHO)18. 
Briefly, each serum sample was serially diluted (from 
1:5 to 1:40) in culture medium (D-MEM, 2% FBS, 
2mM L-glutamine, 100 IU/mL penicillin and 100 μg/
mL streptomycin solution, all from Invitrogen-Gibco, 
USA) and incubated for 1 hour with either the cor-
responding IFNβ preparations at a final concentration 
of 10IU/mL, or with culture medium as control. Every 
serum dilution was tested in duplicate. Thereafter, hu-
man lung carcinoma cell line A549 (ATCC) overnight 
plated into a microtiter 96-well plate (Corning, USA), 
were incubated overnight with serum-IFNβ mixture. 
The cytopathic effect was induced by the addition of 
encephalomyocarditis murine (EMC) virus, at known 
viral activity. After a 24-hour incubation, attached 
cells were stained with 0,2% cresyl violet solution 
(SIGMA, USA) and were diluted with the addition of 
33% acetic acid solution. The absorbance was mea-
sured at 405nm. According to WHO recommenda-
tions, data from the neutralization assay are reported as 
the reciprocal of the highest dilution of serum includ-
ing 50% neutralization (i.e. neutralizing 10IU/mL of 
IFNβ activity to an apparent 1IU/mL of activity). The 
neutralization titer of a serum sample was calculated 
according to Kawade’s formula19,20 and expressed in 
10-fold reduction units per millilitre (TRU/mL)21.
          2.2.2.2.  MxA gene expression analysis
In this method, Nabs titer is determined through the 
quantification of MxA mRNA transcription that is in-
duced from the IFNβ activity in A549 cells.
Serum samples were diluted in culture medium 
(alpha-MEM, 2% FBS, 2mM L-glutamine, 100 IU/
mL penicillin and 100 μg/mL streptomycin solution, 
all from Invitrogen-Gibco, USA) and the appropriate 
IFNβ type in a concentration of 10IU/mL. Then, sam-
ples were incubated for 6.5h with monolayer of A549 
cells plated into 96-well plates (Corning, USA). After 
the incubation, total RNA was extracted using Nucleo-
Spin RNA Extraction kit (Macherey-Nagel) following 
manufacturers’ instructions. For the cDNA synthe-
sis 1μg of RNA was reverse transcribed in a mixture 
containing 2 μg of random hexamers (Biorad) and 
the Omniscript reverse transcription kit (0.5mmol/L 
each dNTP and 0.2U/μL reverse transcriptase, Qia-
gen, Germany). Total reaction volume was 20μL and 
the thermocycler protocol used consisted of a5 min 
denaturation step at 84ο C, a 5 min hexamer hybridiza-
tion step at 64ο C, a 60 min amplification step at 64ο 
C and a final incubation for 10 min at 64ο C. Three 
microlitres of cDNA were added in 27 μL of reac-
tion mixture, containing TAQ Mann Universal Master 
Mix (Applied Biosystems, USA), 25 pmol of MxA 
gene probe (predesigned probes, Applied Biosystems, 
USA) and 25 pmol of 18S rRNA Endogenous control 
(VIC/MGB Probe, Applied Biosystems, USA). The 
latter was used as a housekeeping gene, for the nor-
malization of the MxA gene expression. cDNA was 
amplified in a IQ5 Biorad system after an incubation 
at 95οC for 10min, followed by 40 cycles of denatur-
ation at 95οC for 15sec and amplification at 60 οC for 
60sec The relative quantification was estimated by the 
comparative cycle threshold as outlined by the manu-
facturer. The neutralization titer was determined by 
applying the Kawade’s formula and titers higher than 
20 TRU/mL were considered as positive.
reSultS
A total of 124 patients were included in this study. 
94 patients were tested with cELISA and Western blot 
assay for the detection of binding antibodies and 30 
patients were tested with CPE assay and Real-Time–
PCR for the detection of neutralizing antibodies. 
In the subgroup of the 64 patients (negative for 
Babs in the cELISA assay), who were re-evaluated 
with the WB assay the results were as follows: 49/64 
(76.56%) resulted positive and 15/64 (23.43%) result-
ed negative. (Figure 1, 2) 
In succession, we verified that all 30 Bab-positive 
samples with cELISA resulted positive using the WB 
assay (100%). (Figure 2)
The CPE assay results revealed 15 positive and 
15 negative for Nabs samples. Real-Time-PCR veri-
fied these results in the total of the samples tested 
(100.00%). 
dIScuSSIon
Several large double-blind placebo-controlled clinical 
trials suggest that the proportion of MS patients re-
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ported to have Nabs range from 2% to 45%, whereas 
the respective percentage for the Babs was 81%2,6,8,22-
26. The reason for the immunogenicity of INFβ is not 
known in full detail. There are several factors that 
determine whether administration of a recombinant 
human molecule like INFβ to a MS patient causes de-
velopment of Nabs27. Some factors are patient-linked 
and others are harbored in the INFβ product, i.e., the 
structure of the protein, differences in the glycopro-
teins, dose, route and frequency of administration27. 
It is generally agreed that INFβ-1b is more immu-
nogenic than INFβ-1a28,29. Furthermore, intramuscu-
lar administration induces antibodies less frequently 
than subcutaneous administration28-30. The common 
denominator in all cases is the abatement of therapeu-
tic effect of INFβ2,6,11. Recently, new guidelines were 
postulated in order to incorporate information on Nabs 
status and/or MxA bioavailability in clinical practice 
and therapeutic decision making13. In this regard, it 
is prerequisite to establish and validate detection as-
says that would accurately depict the Babs and Nabs 
status of patients under treatment with INFβ. The ex-
istence of Inter-laboratory and inter-assay variability 
is a well-known negative aspect, even when using the 
same biological assay for analysis of duplicate clinical 
specimens13,31,32. Many factors contribute in impeding 
the reproducibility and accuracy of assays. These in-
clude the conditions of sample distribution, assay tim-
ing, temperature regulation, differing product-specific 
cut-off levels for defining titers as negative, low or 
high, interferon-β subtype used in the assays and op-
erator skills13,31. Moreover, biological parameters may 
affect the results of the assays such as virulence and 
presence of metabolites in clinical material or the met-
abolic state of cell lines31. 
Neutralizing assays are expensive, have difficul-
ties in methodology that limit standardization, and 
are time-consuming, and they cannot be used for 
screening7,33. Therefore binding assays are more ap-
propriate because they provide a less expensive and a 
more rapid screening path. Many investigators utilize 
direct ELISA in which the cytokine is directly coated 
on the plates7,34. This assay presents disadvantages 
which could lead to false-negative and false-positive 
results16. In order to overcome the drawbacks capture 
ELISA was developed, using a monoclonal anti-IFNβ 
antibody to initially capture the antigen16. 
 In the present study the assessment of the results 
suggests that Western blot assay is more sensitive than 
ELISA for the detection of binding antibodies. The su-
periority of Western blotting over ELISA was demon-
strated in a previous study by Chan et al. regarding 
the detection of anti-ribosomal P antibodies in the di-
agnosis of cerebral lupus35. More recently, Di Marco 
et al addressed the problematic issue of detection 
of low-titer Nabs in patients with multiple sclerosis 
treated with interferon beta36. The method was found 
to be rapid, specific and sensitive and consistent with 
respect to well-established antiviral neutralization or 
commercial enzyme-linked immunosorbent assays. 
The gold standard for detecting Nabs to IFNβ has 
been the antiviral CPE assay. It tests the ability of an-
tibodies to interfere with receptor binding by measur-
ing the antiviral effect of IFNβ. Due to the nature of 
this bioassay, it is more prone to variability between 
assays and between laboratories. The World Health 
Organization (WHO) has recommended the use of 
human lung carcinoma (A549) cell line and the en-
cephalomyocarditis virus18 in order to minimize the 
inter-laboratory variability. For quantitative purposes 
the Kawade method was chosen to calculate the titer19. 
The CPE assay possesses two advantages, it is very 
sensitive and it requires a complex cellular response to 
the IFNβ32. The latter is important because the inhibi-
tion of such a response is likely indicative of inhibition 
of multiple IFN pathways, including those important 
for the clinical effect in multiple sclerosis. The disad-
vantage of CPE assay is that it is not specific meaning 
that other compounds present in human serum, such 
interleukin-6 or IFN-γ, can interfere or mimic IFNβ 
antiviral activity and influence the results. Another 
drawback is the fact that it is cumbersome and can 
have high interassay variability37. The in vivo assay 
using myxovirus resistance protein A (MxA) mRNA 
measures the in vivo induction of the MxA gene that 
is specifically induced by IFNβ injected by the pa-
tient. In the present study the assay performed on the 
messenger RNA of this gene used the real-time-PCR 
to determine the in vivo biologic effect of adminis-
tered IFNβ. Advantage of this assay is the fact that 
determines the in vivo biologic response of a specific 
patient to his or her IFNβ therapy. Additionally, it is 
relatively simple, there is large difference between 
pre- and post-dosing and the MxA gene is specific for 
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type I IFNs. A drawback is the time interval between 
IFNβ injection and blood collection32. 
The evaluation of CPE and Real-time-PCR results 
indicates that they possess similar sensitivity. The em-
ployment of the two assays combined has practical 
consequences in treating patients and supporting dif-
ficult or ambiguous decisions. RT-PCR and MxA bio-
activity measurements provide complementary infor-
mation about biological activity especially in patients 
with low Nab titers, intermediate disease activity or 
doing poorly while on treatment with IFNβ13. 
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ΠΕΡΙΛΗΨΗ: Η ιντερφερόνη-β (IFNβ) αποτελεί θεραπεία πρώτης γραμμής για την αντιμετώπιση της υποτροπιάζουσας-
διαλείπουσας σκλήρυνσης κατά πλάκας. Τα σκευάσματα της IFNβ πυροδοτούν την ανάπτυξη συνδετικών (Babs) και εξουδε-
τερωτικών αντισωμάτων (Nabs). Η καταστροφική επίδραση των Nabs αποτυπώνεται από την εξασθένιση του θεραπευτικού 
αποτελέσματος που συνεπάγεται την επιδείνωση κλινικών και ακτινολογικών παραμέτρων. Η συχνότητα παρουσίας και οι 
τίτλοι των Nabs ποικίλλουν ανάλογα με το σκεύασμα IFNβ που χρησιμοποιείται, τη δόση, την συχνότητα και την οδό χορήγη-
σης, τη διάρκεια θεραπείας και την μέθοδο ανίχνευσης που χρησιμοποιείται. Σκοπός της παρούσας μελέτης είναι η εκτίμηση 
της ευαισθησίας των μεθόδων εντοπισμού των συνδετικών και εξουδετερωτικών αντισωμάτων σε ασθενείς με υποτροπιά-
ζουσα-διαλείπουσα σκλήρυνση κατά πλάκας. Η ανάλυση των αποτελεσμάτων προτείνει ότι η μέθοδος ανοσοστυπώματος 
κατά Western είναι πιο ευαίσθητη από την ELISA. Επίσης, προκύπτει ότι η Real-time-PCR και η μέθοδος κυτταροπαθητικού 
αποτελέσματος κατέχουν ίδια αποτελεσματικότητα. Παρ’ όλα αυτά, η μέθοδος κυτταροπαθητικού αποτελέσματος αποτελεί 
την μέθοδο επιλογής για την ανίχνευση των εξουδετερωτικών αντισωμάτων σύμφωνα με τον Παγκόσμιο Οργανισμό Υγείας. 
Τα αποτελέσματά μας συνηγορούν για τη διενέργεια δια-εργαστηριακών μελετών που θα καταλήξουν σε κοινά αποδεκτή 
μέθοδο η οποία θα είναι αξιόπιστη και οικονομική για τον εντοπισμό των Babs και Nabs σε ασθενείς με σκλήρυνση κατά 
πλάκας υπό θεραπεία με IFNβ.
Λέξεις Κλειδιά: Εξουδετερωτικά αντισώματα, Συνδετικά αντισώματα, Ιντερφερόνη-β, Σκλήρυνση κατά πλάκας.
Αξιολόγηση της ευαισθησίας των μεθόδων ανίχνευσης των συνδετικών και  
εξουδετερωτικών αντισωμάτων έναντι της ιντερφερόνης-β σε ασθενείς με υποτροπι-
άζουσα-διαλείπουσα Σκλήρυνση κατά Πλάκας υπό αγωγή με ιντερφερόνης-β -  
Συγκριτική μελέτη.
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